Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Trevi Therapeutics, Inc. (TRVI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/16/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/11/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update Plans to initiate three clinical studies in chronic cough indications for later this year remain on track Data from Phase 2 CANAL trial of chronic cough in patients with idiopathic pulmonary fibrosis published in NEJM Evidence Management to host a conference call and webcast today at 4:30 p.m. EDT New Haven, Conn., August 10, 2023 – Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis , other chronic cough indications, and prurigo nodularis, today announced financial results for the quarter ended June 30, 2023, as well as provided business updates. ..." |
|
| 06/29/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 06/29/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 06/12/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/11/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/14/2023 |
8-K
| Quarterly results |
| 03/16/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/16/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G/A
| Venrock Healthcare Capital Partners II, L.P. reports a 10% stake in Trevi Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Fairmount Funds Management LLC reports a 9.9% stake in TREVI THERAPEUTICS, INC. |
| 02/14/2023 |
SC 13G/A
| ARMISTICE CAPITAL, LLC reports a 5% stake in TREVI THERAPEUTICS, INC. |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 10% stake in Trevi Therapeutics, Inc. |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/10/2022 |
8-K
| Quarterly results |
| 10/07/2022 |
SC 13G
| VIKING GLOBAL INVESTORS LP reports a 10% stake in Trevi Therapeutics, Inc. |
| 10/07/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 09/23/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 09/23/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, by and among the Company and SVB Securities LLC, Stifel, Nicolaus & Company, Incorporated and Oppenheimer & Co. Inc",
"Form of Pre-Funded Warrant",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Trevi Therapeutics Announces Pricing of $55 Million Public Offering New Haven, Conn., September 23, 2022 - Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing an investigational therapy, Haduvio ™ for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis and the treatment of prurigo nodularis , today announced the pricing of its underwritten public offering of 14,252,670 shares of its common stock at a public offering price of $1.93 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase 14,247,330 shares of common stock at a price of $1.929 per pre-funded warrant, for total proceeds of approximately $55 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. The..." |
|
| 09/22/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 09/19/2022 |
8-K
| Investor presentation |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/11/2022 |
8-K
| Quarterly results |
| 06/29/2022 |
8-K
| Quarterly results |
|
|
|